/
Oncology
Breast Neoplasms
26
Pipeline Programs↗
60
Active Trials↗
25
Companies Involved↗
Breast Neoplasms is an emerging landscape with 26 programs across 25 companies. The most active players are Eli Lilly, Merck & Co., Xadcera Biopharmaceutical (Suzhou) Co., Ltd.. 16 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 26
Approved
No programs
Analysis
Modality Breakdown
76%
Small molecule
19 of 25 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 96% of 26 pipeline programs.
Analysis
Trial Status
75
clinical trials
Recruiting30 · 40%
Active, not recruiting19 · 25%
Completed12 · 16%
Not yet recruiting11 · 15%
Withdrawn2 · 3%
Terminated1 · 1%
Clinical Trials
Trial Activity
75 trials
Prospective Study on ICG Lymphography Changes Before and After Radiotherapy in Breast Cancer Patients
Recruiting·—·N/A·NCT07297927·40 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)